Global Active Pharma Ingredient

Active Pharma Ingredient Comprehensive Study by Type (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients), Application (Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Pain Management, Others), Drug (Prescription Drugs, Over-the-counter Drugs), Synthesis (Synthetic API, Biotech API), Manufacturer (Captive API, Merchant API) Players and Region - Global Market Outlook to 2028

Active Pharma Ingredient Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 5.93%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The Active Pharmaceutical Ingredient (API) is the chief therapeutic entity in a drug product and it is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place.

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketAsia Pacific
UnitValue (USD Billion)
Key Companies ProfiledTeva Pharmaceutical Industries Ltd (Israel), Novartis International AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson (United States), Mylan N.V. (United States), BASF SE (Germany), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AbbVie Inc. (United States),, AstraZeneca plc (United Kingdom), North China Pharmaceutical Group (China), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Cambrex (United States)


According to AMA, the market for Active Pharma Ingredient is expected to register a CAGR of 5.93% during the forecast period to 2028. This growth is primarily driven by Rising Incidence of Chronic Diseases like Cancer, Increasing Importance of Generics Medicines in Developing Economies Upsirging Adoption of Organ-On-Chip Models in Drug Development and Growing Focus on Precision Medicine.

Globally, a noticeable market trend is evident Increasing Adoption of Artificial Intelligence-Based Tools for Drug Discovery The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Teva Pharmaceutical Industries Ltd (Israel), Novartis International AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson (United States), Mylan N.V. (United States), BASF SE (Germany), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AbbVie Inc. (United States),, AstraZeneca plc (United Kingdom), North China Pharmaceutical Group (China), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Cambrex (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Developments in the Market:
On 31st January 2020, Sandoz has announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly-owned subsidiary of Aspen Pharmacare Holdings Limited. Sandoz has acquired all of the shares in Aspen Japan K.K. and associated assets held by AGI.
On 14th September 2018, Lonza Pharma & Biotech has announced the launch of its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp (CH) site to address increasing global early-intermediates supply security and quality concerns. Lonza now offers its customers an integrated supply chain from non-GMP early intermediates to cGMP advanced intermediates and APIs.

Influencing Trend:
Increasing Adoption of Artificial Intelligence-Based Tools for Drug Discovery

Market Growth Drivers:
Rising Incidence of Chronic Diseases like Cancer, Increasing Importance of Generics Medicines in Developing Economies Upsirging Adoption of Organ-On-Chip Models in Drug Development and Growing Focus on Precision Medicine

Challenges:
Product Differentiation - A Major Concern for API Manufacturers and High Manufacturing Costs

Restraints:
Unfavorable Drug Price Control Policies Across Various Countries and Increasing Penetration of Counterfeit Drugs

Opportunities:
Technological Advancements and Development in API Manufacturing, Rising Investments in Real-World Evidence By Pharmaceutical Companies and Highly Potent Active Pharmaceutical Ingredients

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Active Pharma Ingredient Market
- Analysis about New Entrants in Active Pharma Ingredient Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Active Pharma Ingredient Study Sheds Light on
— The Active Pharma Ingredient Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Active Pharma Ingredient industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Active Pharma Ingredient industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Innovative Active Pharmaceutical Ingredients
  • Generic Active Pharmaceutical Ingredients
By Application
  • Oncology
  • Cardiovascular Disease
  • Diabetes
  • Central Nervous System and Neurological Disorders
  • Endocrinology
  • Pain Management
  • Others
By Drug
  • Prescription Drugs
  • Over-the-counter Drugs

By Synthesis
  • Synthetic API
  • Biotech API

By Manufacturer
  • Captive API
  • Merchant API

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Chronic Diseases like Cancer
      • 3.2.2. Increasing Importance of Generics Medicines in Developing Economies Upsirging Adoption of Organ-On-Chip Models in Drug Development
      • 3.2.3. Growing Focus on Precision Medicine
    • 3.3. Market Challenges
      • 3.3.1. Product Differentiation - A Major Concern for API Manufacturers
      • 3.3.2. High Manufacturing Costs
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Artificial Intelligence-Based Tools for Drug Discovery
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Active Pharma Ingredient, by Type, Application, Drug, Synthesis, Manufacturer and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Active Pharma Ingredient (Value)
      • 5.2.1. Global Active Pharma Ingredient by: Type (Value)
        • 5.2.1.1. Innovative Active Pharmaceutical Ingredients
        • 5.2.1.2. Generic Active Pharmaceutical Ingredients
      • 5.2.2. Global Active Pharma Ingredient by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Cardiovascular Disease
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Central Nervous System and Neurological Disorders
        • 5.2.2.5. Endocrinology
        • 5.2.2.6. Pain Management
        • 5.2.2.7. Others
      • 5.2.3. Global Active Pharma Ingredient by: Drug (Value)
        • 5.2.3.1. Prescription Drugs
        • 5.2.3.2. Over-the-counter Drugs
      • 5.2.4. Global Active Pharma Ingredient by: Synthesis (Value)
        • 5.2.4.1. Synthetic API
        • 5.2.4.2. Biotech API
      • 5.2.5. Global Active Pharma Ingredient by: Manufacturer (Value)
        • 5.2.5.1. Captive API
        • 5.2.5.2. Merchant API
      • 5.2.6. Global Active Pharma Ingredient Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Active Pharma Ingredient (Volume)
      • 5.3.1. Global Active Pharma Ingredient by: Type (Volume)
        • 5.3.1.1. Innovative Active Pharmaceutical Ingredients
        • 5.3.1.2. Generic Active Pharmaceutical Ingredients
      • 5.3.2. Global Active Pharma Ingredient by: Application (Volume)
        • 5.3.2.1. Oncology
        • 5.3.2.2. Cardiovascular Disease
        • 5.3.2.3. Diabetes
        • 5.3.2.4. Central Nervous System and Neurological Disorders
        • 5.3.2.5. Endocrinology
        • 5.3.2.6. Pain Management
        • 5.3.2.7. Others
      • 5.3.3. Global Active Pharma Ingredient by: Drug (Volume)
        • 5.3.3.1. Prescription Drugs
        • 5.3.3.2. Over-the-counter Drugs
      • 5.3.4. Global Active Pharma Ingredient by: Synthesis (Volume)
        • 5.3.4.1. Synthetic API
        • 5.3.4.2. Biotech API
      • 5.3.5. Global Active Pharma Ingredient by: Manufacturer (Volume)
        • 5.3.5.1. Captive API
        • 5.3.5.2. Merchant API
      • 5.3.6. Global Active Pharma Ingredient Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Active Pharma Ingredient (Price)
      • 5.4.1. Global Active Pharma Ingredient by: Type (Price)
  • 6. Active Pharma Ingredient: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan N.V. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BASF SE (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie Inc. (United States),
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. North China Pharmaceutical Group (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Dr. Reddy’s Laboratories Ltd. (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Bayer AG (Germany)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Cambrex (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Active Pharma Ingredient Sale, by Type, Application, Drug, Synthesis, Manufacturer and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Active Pharma Ingredient (Value)
      • 7.2.1. Global Active Pharma Ingredient by: Type (Value)
        • 7.2.1.1. Innovative Active Pharmaceutical Ingredients
        • 7.2.1.2. Generic Active Pharmaceutical Ingredients
      • 7.2.2. Global Active Pharma Ingredient by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Cardiovascular Disease
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Central Nervous System and Neurological Disorders
        • 7.2.2.5. Endocrinology
        • 7.2.2.6. Pain Management
        • 7.2.2.7. Others
      • 7.2.3. Global Active Pharma Ingredient by: Drug (Value)
        • 7.2.3.1. Prescription Drugs
        • 7.2.3.2. Over-the-counter Drugs
      • 7.2.4. Global Active Pharma Ingredient by: Synthesis (Value)
        • 7.2.4.1. Synthetic API
        • 7.2.4.2. Biotech API
      • 7.2.5. Global Active Pharma Ingredient by: Manufacturer (Value)
        • 7.2.5.1. Captive API
        • 7.2.5.2. Merchant API
      • 7.2.6. Global Active Pharma Ingredient Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Active Pharma Ingredient (Volume)
      • 7.3.1. Global Active Pharma Ingredient by: Type (Volume)
        • 7.3.1.1. Innovative Active Pharmaceutical Ingredients
        • 7.3.1.2. Generic Active Pharmaceutical Ingredients
      • 7.3.2. Global Active Pharma Ingredient by: Application (Volume)
        • 7.3.2.1. Oncology
        • 7.3.2.2. Cardiovascular Disease
        • 7.3.2.3. Diabetes
        • 7.3.2.4. Central Nervous System and Neurological Disorders
        • 7.3.2.5. Endocrinology
        • 7.3.2.6. Pain Management
        • 7.3.2.7. Others
      • 7.3.3. Global Active Pharma Ingredient by: Drug (Volume)
        • 7.3.3.1. Prescription Drugs
        • 7.3.3.2. Over-the-counter Drugs
      • 7.3.4. Global Active Pharma Ingredient by: Synthesis (Volume)
        • 7.3.4.1. Synthetic API
        • 7.3.4.2. Biotech API
      • 7.3.5. Global Active Pharma Ingredient by: Manufacturer (Volume)
        • 7.3.5.1. Captive API
        • 7.3.5.2. Merchant API
      • 7.3.6. Global Active Pharma Ingredient Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Active Pharma Ingredient (Price)
      • 7.4.1. Global Active Pharma Ingredient by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Active Pharma Ingredient: by Type(USD Billion)
  • Table 2. Active Pharma Ingredient Innovative Active Pharmaceutical Ingredients , by Region USD Billion (2017-2022)
  • Table 3. Active Pharma Ingredient Generic Active Pharmaceutical Ingredients , by Region USD Billion (2017-2022)
  • Table 4. Active Pharma Ingredient: by Application(USD Billion)
  • Table 5. Active Pharma Ingredient Oncology , by Region USD Billion (2017-2022)
  • Table 6. Active Pharma Ingredient Cardiovascular Disease , by Region USD Billion (2017-2022)
  • Table 7. Active Pharma Ingredient Diabetes , by Region USD Billion (2017-2022)
  • Table 8. Active Pharma Ingredient Central Nervous System and Neurological Disorders , by Region USD Billion (2017-2022)
  • Table 9. Active Pharma Ingredient Endocrinology , by Region USD Billion (2017-2022)
  • Table 10. Active Pharma Ingredient Pain Management , by Region USD Billion (2017-2022)
  • Table 11. Active Pharma Ingredient Others , by Region USD Billion (2017-2022)
  • Table 12. Active Pharma Ingredient: by Drug(USD Billion)
  • Table 13. Active Pharma Ingredient Prescription Drugs , by Region USD Billion (2017-2022)
  • Table 14. Active Pharma Ingredient Over-the-counter Drugs , by Region USD Billion (2017-2022)
  • Table 15. Active Pharma Ingredient: by Synthesis(USD Billion)
  • Table 16. Active Pharma Ingredient Synthetic API , by Region USD Billion (2017-2022)
  • Table 17. Active Pharma Ingredient Biotech API , by Region USD Billion (2017-2022)
  • Table 18. Active Pharma Ingredient: by Manufacturer(USD Billion)
  • Table 19. Active Pharma Ingredient Captive API , by Region USD Billion (2017-2022)
  • Table 20. Active Pharma Ingredient Merchant API , by Region USD Billion (2017-2022)
  • Table 21. South America Active Pharma Ingredient, by Country USD Billion (2017-2022)
  • Table 22. South America Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 23. South America Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 24. South America Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 25. South America Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 26. South America Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 27. Brazil Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 28. Brazil Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 29. Brazil Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 30. Brazil Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 31. Brazil Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 32. Argentina Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 33. Argentina Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 34. Argentina Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 35. Argentina Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 36. Argentina Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 37. Rest of South America Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 38. Rest of South America Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 39. Rest of South America Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 40. Rest of South America Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 41. Rest of South America Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 42. Asia Pacific Active Pharma Ingredient, by Country USD Billion (2017-2022)
  • Table 43. Asia Pacific Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 44. Asia Pacific Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 45. Asia Pacific Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 46. Asia Pacific Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 47. Asia Pacific Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 48. China Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 49. China Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 50. China Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 51. China Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 52. China Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 53. Japan Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 54. Japan Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 55. Japan Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 56. Japan Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 57. Japan Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 58. India Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 59. India Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 60. India Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 61. India Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 62. India Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 63. South Korea Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 64. South Korea Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 65. South Korea Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 66. South Korea Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 67. South Korea Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 68. Taiwan Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 69. Taiwan Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 70. Taiwan Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 71. Taiwan Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 72. Taiwan Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 73. Australia Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 74. Australia Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 75. Australia Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 76. Australia Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 77. Australia Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 78. Rest of Asia-Pacific Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 79. Rest of Asia-Pacific Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 80. Rest of Asia-Pacific Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 81. Rest of Asia-Pacific Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 82. Rest of Asia-Pacific Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 83. Europe Active Pharma Ingredient, by Country USD Billion (2017-2022)
  • Table 84. Europe Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 85. Europe Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 86. Europe Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 87. Europe Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 88. Europe Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 89. Germany Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 90. Germany Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 91. Germany Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 92. Germany Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 93. Germany Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 94. France Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 95. France Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 96. France Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 97. France Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 98. France Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 99. Italy Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 100. Italy Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 101. Italy Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 102. Italy Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 103. Italy Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 104. United Kingdom Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 105. United Kingdom Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 106. United Kingdom Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 107. United Kingdom Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 108. United Kingdom Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 109. Netherlands Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 110. Netherlands Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 111. Netherlands Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 112. Netherlands Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 113. Netherlands Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 114. Rest of Europe Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 115. Rest of Europe Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 116. Rest of Europe Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 117. Rest of Europe Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 118. Rest of Europe Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 119. MEA Active Pharma Ingredient, by Country USD Billion (2017-2022)
  • Table 120. MEA Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 121. MEA Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 122. MEA Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 123. MEA Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 124. MEA Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 125. Middle East Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 126. Middle East Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 127. Middle East Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 128. Middle East Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 129. Middle East Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 130. Africa Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 131. Africa Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 132. Africa Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 133. Africa Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 134. Africa Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 135. North America Active Pharma Ingredient, by Country USD Billion (2017-2022)
  • Table 136. North America Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 137. North America Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 138. North America Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 139. North America Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 140. North America Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 141. United States Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 142. United States Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 143. United States Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 144. United States Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 145. United States Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 146. Canada Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 147. Canada Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 148. Canada Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 149. Canada Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 150. Canada Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 151. Mexico Active Pharma Ingredient, by Type USD Billion (2017-2022)
  • Table 152. Mexico Active Pharma Ingredient, by Application USD Billion (2017-2022)
  • Table 153. Mexico Active Pharma Ingredient, by Drug USD Billion (2017-2022)
  • Table 154. Mexico Active Pharma Ingredient, by Synthesis USD Billion (2017-2022)
  • Table 155. Mexico Active Pharma Ingredient, by Manufacturer USD Billion (2017-2022)
  • Table 156. Active Pharma Ingredient Sales: by Type(Tonne)
  • Table 157. Active Pharma Ingredient Sales Innovative Active Pharmaceutical Ingredients , by Region Tonne (2017-2022)
  • Table 158. Active Pharma Ingredient Sales Generic Active Pharmaceutical Ingredients , by Region Tonne (2017-2022)
  • Table 159. Active Pharma Ingredient Sales: by Application(Tonne)
  • Table 160. Active Pharma Ingredient Sales Oncology , by Region Tonne (2017-2022)
  • Table 161. Active Pharma Ingredient Sales Cardiovascular Disease , by Region Tonne (2017-2022)
  • Table 162. Active Pharma Ingredient Sales Diabetes , by Region Tonne (2017-2022)
  • Table 163. Active Pharma Ingredient Sales Central Nervous System and Neurological Disorders , by Region Tonne (2017-2022)
  • Table 164. Active Pharma Ingredient Sales Endocrinology , by Region Tonne (2017-2022)
  • Table 165. Active Pharma Ingredient Sales Pain Management , by Region Tonne (2017-2022)
  • Table 166. Active Pharma Ingredient Sales Others , by Region Tonne (2017-2022)
  • Table 167. Active Pharma Ingredient Sales: by Drug(Tonne)
  • Table 168. Active Pharma Ingredient Sales Prescription Drugs , by Region Tonne (2017-2022)
  • Table 169. Active Pharma Ingredient Sales Over-the-counter Drugs , by Region Tonne (2017-2022)
  • Table 170. Active Pharma Ingredient Sales: by Synthesis(Tonne)
  • Table 171. Active Pharma Ingredient Sales Synthetic API , by Region Tonne (2017-2022)
  • Table 172. Active Pharma Ingredient Sales Biotech API , by Region Tonne (2017-2022)
  • Table 173. Active Pharma Ingredient Sales: by Manufacturer(Tonne)
  • Table 174. Active Pharma Ingredient Sales Captive API , by Region Tonne (2017-2022)
  • Table 175. Active Pharma Ingredient Sales Merchant API , by Region Tonne (2017-2022)
  • Table 176. South America Active Pharma Ingredient Sales, by Country Tonne (2017-2022)
  • Table 177. South America Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 178. South America Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 179. South America Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 180. South America Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 181. South America Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 182. Brazil Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 183. Brazil Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 184. Brazil Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 185. Brazil Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 186. Brazil Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 187. Argentina Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 188. Argentina Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 189. Argentina Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 190. Argentina Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 191. Argentina Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 192. Rest of South America Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 193. Rest of South America Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 194. Rest of South America Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 195. Rest of South America Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 196. Rest of South America Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 197. Asia Pacific Active Pharma Ingredient Sales, by Country Tonne (2017-2022)
  • Table 198. Asia Pacific Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 199. Asia Pacific Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 200. Asia Pacific Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 201. Asia Pacific Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 202. Asia Pacific Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 203. China Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 204. China Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 205. China Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 206. China Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 207. China Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 208. Japan Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 209. Japan Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 210. Japan Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 211. Japan Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 212. Japan Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 213. India Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 214. India Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 215. India Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 216. India Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 217. India Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 218. South Korea Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 219. South Korea Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 220. South Korea Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 221. South Korea Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 222. South Korea Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 223. Taiwan Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 224. Taiwan Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 225. Taiwan Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 226. Taiwan Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 227. Taiwan Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 228. Australia Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 229. Australia Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 230. Australia Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 231. Australia Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 232. Australia Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 233. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 234. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 235. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 236. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 237. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 238. Europe Active Pharma Ingredient Sales, by Country Tonne (2017-2022)
  • Table 239. Europe Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 240. Europe Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 241. Europe Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 242. Europe Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 243. Europe Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 244. Germany Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 245. Germany Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 246. Germany Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 247. Germany Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 248. Germany Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 249. France Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 250. France Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 251. France Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 252. France Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 253. France Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 254. Italy Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 255. Italy Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 256. Italy Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 257. Italy Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 258. Italy Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 259. United Kingdom Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 260. United Kingdom Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 261. United Kingdom Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 262. United Kingdom Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 263. United Kingdom Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 264. Netherlands Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 265. Netherlands Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 266. Netherlands Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 267. Netherlands Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 268. Netherlands Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 269. Rest of Europe Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 270. Rest of Europe Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 271. Rest of Europe Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 272. Rest of Europe Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 273. Rest of Europe Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 274. MEA Active Pharma Ingredient Sales, by Country Tonne (2017-2022)
  • Table 275. MEA Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 276. MEA Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 277. MEA Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 278. MEA Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 279. MEA Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 280. Middle East Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 281. Middle East Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 282. Middle East Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 283. Middle East Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 284. Middle East Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 285. Africa Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 286. Africa Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 287. Africa Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 288. Africa Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 289. Africa Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 290. North America Active Pharma Ingredient Sales, by Country Tonne (2017-2022)
  • Table 291. North America Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 292. North America Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 293. North America Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 294. North America Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 295. North America Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 296. United States Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 297. United States Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 298. United States Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 299. United States Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 300. United States Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 301. Canada Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 302. Canada Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 303. Canada Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 304. Canada Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 305. Canada Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 306. Mexico Active Pharma Ingredient Sales, by Type Tonne (2017-2022)
  • Table 307. Mexico Active Pharma Ingredient Sales, by Application Tonne (2017-2022)
  • Table 308. Mexico Active Pharma Ingredient Sales, by Drug Tonne (2017-2022)
  • Table 309. Mexico Active Pharma Ingredient Sales, by Synthesis Tonne (2017-2022)
  • Table 310. Mexico Active Pharma Ingredient Sales, by Manufacturer Tonne (2017-2022)
  • Table 311. Active Pharma Ingredient: by Type(USD/Units)
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Active Pharma Ingredient: by Type(USD Billion)
  • Table 328. Active Pharma Ingredient Innovative Active Pharmaceutical Ingredients , by Region USD Billion (2023-2028)
  • Table 329. Active Pharma Ingredient Generic Active Pharmaceutical Ingredients , by Region USD Billion (2023-2028)
  • Table 330. Active Pharma Ingredient: by Application(USD Billion)
  • Table 331. Active Pharma Ingredient Oncology , by Region USD Billion (2023-2028)
  • Table 332. Active Pharma Ingredient Cardiovascular Disease , by Region USD Billion (2023-2028)
  • Table 333. Active Pharma Ingredient Diabetes , by Region USD Billion (2023-2028)
  • Table 334. Active Pharma Ingredient Central Nervous System and Neurological Disorders , by Region USD Billion (2023-2028)
  • Table 335. Active Pharma Ingredient Endocrinology , by Region USD Billion (2023-2028)
  • Table 336. Active Pharma Ingredient Pain Management , by Region USD Billion (2023-2028)
  • Table 337. Active Pharma Ingredient Others , by Region USD Billion (2023-2028)
  • Table 338. Active Pharma Ingredient: by Drug(USD Billion)
  • Table 339. Active Pharma Ingredient Prescription Drugs , by Region USD Billion (2023-2028)
  • Table 340. Active Pharma Ingredient Over-the-counter Drugs , by Region USD Billion (2023-2028)
  • Table 341. Active Pharma Ingredient: by Synthesis(USD Billion)
  • Table 342. Active Pharma Ingredient Synthetic API , by Region USD Billion (2023-2028)
  • Table 343. Active Pharma Ingredient Biotech API , by Region USD Billion (2023-2028)
  • Table 344. Active Pharma Ingredient: by Manufacturer(USD Billion)
  • Table 345. Active Pharma Ingredient Captive API , by Region USD Billion (2023-2028)
  • Table 346. Active Pharma Ingredient Merchant API , by Region USD Billion (2023-2028)
  • Table 347. South America Active Pharma Ingredient, by Country USD Billion (2023-2028)
  • Table 348. South America Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 349. South America Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 350. South America Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 351. South America Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 352. South America Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 353. Brazil Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 354. Brazil Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 355. Brazil Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 356. Brazil Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 357. Brazil Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 358. Argentina Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 359. Argentina Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 360. Argentina Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 361. Argentina Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 362. Argentina Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 363. Rest of South America Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 364. Rest of South America Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 365. Rest of South America Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 366. Rest of South America Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 367. Rest of South America Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 368. Asia Pacific Active Pharma Ingredient, by Country USD Billion (2023-2028)
  • Table 369. Asia Pacific Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 370. Asia Pacific Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 371. Asia Pacific Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 372. Asia Pacific Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 373. Asia Pacific Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 374. China Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 375. China Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 376. China Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 377. China Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 378. China Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 379. Japan Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 380. Japan Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 381. Japan Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 382. Japan Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 383. Japan Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 384. India Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 385. India Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 386. India Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 387. India Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 388. India Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 389. South Korea Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 390. South Korea Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 391. South Korea Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 392. South Korea Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 393. South Korea Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 394. Taiwan Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 395. Taiwan Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 396. Taiwan Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 397. Taiwan Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 398. Taiwan Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 399. Australia Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 400. Australia Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 401. Australia Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 402. Australia Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 403. Australia Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 404. Rest of Asia-Pacific Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 405. Rest of Asia-Pacific Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 406. Rest of Asia-Pacific Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 407. Rest of Asia-Pacific Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 408. Rest of Asia-Pacific Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 409. Europe Active Pharma Ingredient, by Country USD Billion (2023-2028)
  • Table 410. Europe Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 411. Europe Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 412. Europe Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 413. Europe Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 414. Europe Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 415. Germany Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 416. Germany Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 417. Germany Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 418. Germany Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 419. Germany Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 420. France Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 421. France Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 422. France Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 423. France Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 424. France Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 425. Italy Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 426. Italy Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 427. Italy Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 428. Italy Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 429. Italy Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 430. United Kingdom Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 431. United Kingdom Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 432. United Kingdom Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 433. United Kingdom Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 434. United Kingdom Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 435. Netherlands Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 436. Netherlands Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 437. Netherlands Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 438. Netherlands Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 439. Netherlands Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 440. Rest of Europe Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 441. Rest of Europe Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 442. Rest of Europe Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 443. Rest of Europe Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 444. Rest of Europe Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 445. MEA Active Pharma Ingredient, by Country USD Billion (2023-2028)
  • Table 446. MEA Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 447. MEA Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 448. MEA Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 449. MEA Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 450. MEA Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 451. Middle East Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 452. Middle East Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 453. Middle East Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 454. Middle East Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 455. Middle East Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 456. Africa Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 457. Africa Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 458. Africa Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 459. Africa Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 460. Africa Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 461. North America Active Pharma Ingredient, by Country USD Billion (2023-2028)
  • Table 462. North America Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 463. North America Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 464. North America Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 465. North America Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 466. North America Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 467. United States Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 468. United States Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 469. United States Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 470. United States Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 471. United States Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 472. Canada Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 473. Canada Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 474. Canada Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 475. Canada Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 476. Canada Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 477. Mexico Active Pharma Ingredient, by Type USD Billion (2023-2028)
  • Table 478. Mexico Active Pharma Ingredient, by Application USD Billion (2023-2028)
  • Table 479. Mexico Active Pharma Ingredient, by Drug USD Billion (2023-2028)
  • Table 480. Mexico Active Pharma Ingredient, by Synthesis USD Billion (2023-2028)
  • Table 481. Mexico Active Pharma Ingredient, by Manufacturer USD Billion (2023-2028)
  • Table 482. Active Pharma Ingredient Sales: by Type(Tonne)
  • Table 483. Active Pharma Ingredient Sales Innovative Active Pharmaceutical Ingredients , by Region Tonne (2023-2028)
  • Table 484. Active Pharma Ingredient Sales Generic Active Pharmaceutical Ingredients , by Region Tonne (2023-2028)
  • Table 485. Active Pharma Ingredient Sales: by Application(Tonne)
  • Table 486. Active Pharma Ingredient Sales Oncology , by Region Tonne (2023-2028)
  • Table 487. Active Pharma Ingredient Sales Cardiovascular Disease , by Region Tonne (2023-2028)
  • Table 488. Active Pharma Ingredient Sales Diabetes , by Region Tonne (2023-2028)
  • Table 489. Active Pharma Ingredient Sales Central Nervous System and Neurological Disorders , by Region Tonne (2023-2028)
  • Table 490. Active Pharma Ingredient Sales Endocrinology , by Region Tonne (2023-2028)
  • Table 491. Active Pharma Ingredient Sales Pain Management , by Region Tonne (2023-2028)
  • Table 492. Active Pharma Ingredient Sales Others , by Region Tonne (2023-2028)
  • Table 493. Active Pharma Ingredient Sales: by Drug(Tonne)
  • Table 494. Active Pharma Ingredient Sales Prescription Drugs , by Region Tonne (2023-2028)
  • Table 495. Active Pharma Ingredient Sales Over-the-counter Drugs , by Region Tonne (2023-2028)
  • Table 496. Active Pharma Ingredient Sales: by Synthesis(Tonne)
  • Table 497. Active Pharma Ingredient Sales Synthetic API , by Region Tonne (2023-2028)
  • Table 498. Active Pharma Ingredient Sales Biotech API , by Region Tonne (2023-2028)
  • Table 499. Active Pharma Ingredient Sales: by Manufacturer(Tonne)
  • Table 500. Active Pharma Ingredient Sales Captive API , by Region Tonne (2023-2028)
  • Table 501. Active Pharma Ingredient Sales Merchant API , by Region Tonne (2023-2028)
  • Table 502. South America Active Pharma Ingredient Sales, by Country Tonne (2023-2028)
  • Table 503. South America Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 504. South America Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 505. South America Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 506. South America Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 507. South America Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 508. Brazil Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 509. Brazil Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 510. Brazil Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 511. Brazil Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 512. Brazil Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 513. Argentina Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 514. Argentina Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 515. Argentina Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 516. Argentina Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 517. Argentina Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 518. Rest of South America Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 519. Rest of South America Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 520. Rest of South America Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 521. Rest of South America Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 522. Rest of South America Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 523. Asia Pacific Active Pharma Ingredient Sales, by Country Tonne (2023-2028)
  • Table 524. Asia Pacific Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 525. Asia Pacific Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 526. Asia Pacific Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 527. Asia Pacific Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 528. Asia Pacific Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 529. China Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 530. China Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 531. China Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 532. China Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 533. China Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 534. Japan Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 535. Japan Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 536. Japan Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 537. Japan Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 538. Japan Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 539. India Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 540. India Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 541. India Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 542. India Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 543. India Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 544. South Korea Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 545. South Korea Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 546. South Korea Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 547. South Korea Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 548. South Korea Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 549. Taiwan Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 550. Taiwan Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 551. Taiwan Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 552. Taiwan Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 553. Taiwan Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 554. Australia Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 555. Australia Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 556. Australia Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 557. Australia Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 558. Australia Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 559. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 560. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 561. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 562. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 563. Rest of Asia-Pacific Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 564. Europe Active Pharma Ingredient Sales, by Country Tonne (2023-2028)
  • Table 565. Europe Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 566. Europe Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 567. Europe Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 568. Europe Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 569. Europe Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 570. Germany Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 571. Germany Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 572. Germany Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 573. Germany Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 574. Germany Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 575. France Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 576. France Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 577. France Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 578. France Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 579. France Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 580. Italy Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 581. Italy Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 582. Italy Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 583. Italy Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 584. Italy Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 585. United Kingdom Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 586. United Kingdom Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 587. United Kingdom Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 588. United Kingdom Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 589. United Kingdom Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 590. Netherlands Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 591. Netherlands Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 592. Netherlands Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 593. Netherlands Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 594. Netherlands Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 595. Rest of Europe Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 596. Rest of Europe Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 597. Rest of Europe Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 598. Rest of Europe Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 599. Rest of Europe Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 600. MEA Active Pharma Ingredient Sales, by Country Tonne (2023-2028)
  • Table 601. MEA Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 602. MEA Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 603. MEA Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 604. MEA Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 605. MEA Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 606. Middle East Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 607. Middle East Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 608. Middle East Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 609. Middle East Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 610. Middle East Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 611. Africa Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 612. Africa Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 613. Africa Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 614. Africa Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 615. Africa Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 616. North America Active Pharma Ingredient Sales, by Country Tonne (2023-2028)
  • Table 617. North America Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 618. North America Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 619. North America Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 620. North America Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 621. North America Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 622. United States Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 623. United States Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 624. United States Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 625. United States Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 626. United States Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 627. Canada Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 628. Canada Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 629. Canada Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 630. Canada Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 631. Canada Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 632. Mexico Active Pharma Ingredient Sales, by Type Tonne (2023-2028)
  • Table 633. Mexico Active Pharma Ingredient Sales, by Application Tonne (2023-2028)
  • Table 634. Mexico Active Pharma Ingredient Sales, by Drug Tonne (2023-2028)
  • Table 635. Mexico Active Pharma Ingredient Sales, by Synthesis Tonne (2023-2028)
  • Table 636. Mexico Active Pharma Ingredient Sales, by Manufacturer Tonne (2023-2028)
  • Table 637. Active Pharma Ingredient: by Type(USD/Units)
  • Table 638. Research Programs/Design for This Report
  • Table 639. Key Data Information from Secondary Sources
  • Table 640. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Active Pharma Ingredient: by Type USD Billion (2017-2022)
  • Figure 5. Global Active Pharma Ingredient: by Application USD Billion (2017-2022)
  • Figure 6. Global Active Pharma Ingredient: by Drug USD Billion (2017-2022)
  • Figure 7. Global Active Pharma Ingredient: by Synthesis USD Billion (2017-2022)
  • Figure 8. Global Active Pharma Ingredient: by Manufacturer USD Billion (2017-2022)
  • Figure 9. South America Active Pharma Ingredient Share (%), by Country
  • Figure 10. Asia Pacific Active Pharma Ingredient Share (%), by Country
  • Figure 11. Europe Active Pharma Ingredient Share (%), by Country
  • Figure 12. MEA Active Pharma Ingredient Share (%), by Country
  • Figure 13. North America Active Pharma Ingredient Share (%), by Country
  • Figure 14. Global Active Pharma Ingredient: by Type Tonne (2017-2022)
  • Figure 15. Global Active Pharma Ingredient: by Application Tonne (2017-2022)
  • Figure 16. Global Active Pharma Ingredient: by Drug Tonne (2017-2022)
  • Figure 17. Global Active Pharma Ingredient: by Synthesis Tonne (2017-2022)
  • Figure 18. Global Active Pharma Ingredient: by Manufacturer Tonne (2017-2022)
  • Figure 19. South America Active Pharma Ingredient Share (%), by Country
  • Figure 20. Asia Pacific Active Pharma Ingredient Share (%), by Country
  • Figure 21. Europe Active Pharma Ingredient Share (%), by Country
  • Figure 22. MEA Active Pharma Ingredient Share (%), by Country
  • Figure 23. North America Active Pharma Ingredient Share (%), by Country
  • Figure 24. Global Active Pharma Ingredient: by Type USD/Units (2017-2022)
  • Figure 25. Global Active Pharma Ingredient share by Players 2022 (%)
  • Figure 26. Global Active Pharma Ingredient share by Players (Top 3) 2022(%)
  • Figure 27. Global Active Pharma Ingredient share by Players (Top 5) 2022(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2022
  • Figure 31. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 37. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 39. BASF SE (Germany) Revenue, Net Income and Gross profit
  • Figure 40. BASF SE (Germany) Revenue: by Geography 2022
  • Figure 41. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 43. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 45. AbbVie Inc. (United States), Revenue, Net Income and Gross profit
  • Figure 46. AbbVie Inc. (United States), Revenue: by Geography 2022
  • Figure 47. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 48. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 49. North China Pharmaceutical Group (China) Revenue, Net Income and Gross profit
  • Figure 50. North China Pharmaceutical Group (China) Revenue: by Geography 2022
  • Figure 51. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 52. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2022
  • Figure 53. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 54. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 55. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 56. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 57. Cambrex (United States) Revenue, Net Income and Gross profit
  • Figure 58. Cambrex (United States) Revenue: by Geography 2022
  • Figure 59. Global Active Pharma Ingredient: by Type USD Billion (2023-2028)
  • Figure 60. Global Active Pharma Ingredient: by Application USD Billion (2023-2028)
  • Figure 61. Global Active Pharma Ingredient: by Drug USD Billion (2023-2028)
  • Figure 62. Global Active Pharma Ingredient: by Synthesis USD Billion (2023-2028)
  • Figure 63. Global Active Pharma Ingredient: by Manufacturer USD Billion (2023-2028)
  • Figure 64. South America Active Pharma Ingredient Share (%), by Country
  • Figure 65. Asia Pacific Active Pharma Ingredient Share (%), by Country
  • Figure 66. Europe Active Pharma Ingredient Share (%), by Country
  • Figure 67. MEA Active Pharma Ingredient Share (%), by Country
  • Figure 68. North America Active Pharma Ingredient Share (%), by Country
  • Figure 69. Global Active Pharma Ingredient: by Type Tonne (2023-2028)
  • Figure 70. Global Active Pharma Ingredient: by Application Tonne (2023-2028)
  • Figure 71. Global Active Pharma Ingredient: by Drug Tonne (2023-2028)
  • Figure 72. Global Active Pharma Ingredient: by Synthesis Tonne (2023-2028)
  • Figure 73. Global Active Pharma Ingredient: by Manufacturer Tonne (2023-2028)
  • Figure 74. South America Active Pharma Ingredient Share (%), by Country
  • Figure 75. Asia Pacific Active Pharma Ingredient Share (%), by Country
  • Figure 76. Europe Active Pharma Ingredient Share (%), by Country
  • Figure 77. MEA Active Pharma Ingredient Share (%), by Country
  • Figure 78. North America Active Pharma Ingredient Share (%), by Country
  • Figure 79. Global Active Pharma Ingredient: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Mylan N.V. (United States)
  • BASF SE (Germany)
  • GlaxoSmithKline plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • AbbVie Inc. (United States),
  • AstraZeneca plc (United Kingdom)
  • North China Pharmaceutical Group (China)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Cambrex (United States)
Additional players considered in the study are as follows:
Aurobindo Pharma (India) , Sun Pharmaceutical Industries (India) , Boehringer Ingelheim GmbH (Germany) , Koninklijke DSM N.V. (Netherlands) , Zhejiang Medicine Co., Ltd. (China) , Biocon Limited (India) , Johnson Matthey (United Kingdom) , Zhejiang Hisun Pharmaceutical Co. Ltd (China) , Shandong Xinhua Pharmaceutical (China) , Lonza Group (Switzerland) , Huahai Pharmaceutical (China) , Haerbin Pharmaceutical Group (China)
Select User Access Type

Key Highlights of Report


May 2023 226 Pages 52 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Active Pharma Ingredient Quantitative research analysis
Global Active Pharma Ingredient Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Active Pharma Ingredient market are Teva Pharmaceutical Industries Ltd (Israel), Novartis International AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson (United States), Mylan N.V. (United States), BASF SE (Germany), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), AbbVie Inc. (United States),, AstraZeneca plc (United Kingdom), North China Pharmaceutical Group (China), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Cambrex (United States), to name a few.
North America is dominating the Active Pharma Ingredient Market.
"Product Differentiation - A Major Concern for API Manufacturers " is seen as one of the major challenges by many Industry Players of Active Pharma Ingredient Market
The Active Pharma Ingredient market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Active Pharma Ingredient market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Active Pharma Ingredient Report?

Have a Query? Click Here

Other Related Reports

Kinase Inhibitors Comprehensive Study by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase I...
$ 3750
Eye Care Products Comprehensive Study by Type (Artificial Tear Drops, Ointments or Emollients, Eye Washes, Hyperosomotics, Eyelid Scrubs, Decongestants, Antihistamines), Form (Cream, Solution, Other...
$ 3450
Calcitriol Comprehensive Study by Application (Osteoporosis, Renal Osteodystrophy, Others), Distribution Channel (Offline, Online), Form (Calcitriol Capsule, Calcitriol Solution), Disease Indication ...
$ 3450
Birth Control Pills Comprehensive Study by Type (Oral Contraceptives, Contraceptive Injectable), Application (Hospital Pharmacy, Independent Pharmacy, Online Platform, Clinics), Purchase Mode (Offlin...
$ 3500
OTC Drug Comprehensive Study by Type (Class A, Class B), Application (Allergy Prevention & Treatment, Antacids and Acid Reducers, Anticandial, Antihistamines, Antidiarrheal and Laxatives, Anti-fungal...
$ 3450
Biopharmaceutical Logistics Comprehensive Study by Type (Cold Chain Logistics, Non-Cold Chain Logistics), End Users (Clinics, Pharmacies, Hospitals, Pharmaceuticals, Biopharmaceuticals, Supermarkets,...
$ 3450